Publications by authors named "John D Powderly"

Claim this Profile
F
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.
Martin E Gutierrez, Shou-Ching Tang, John D Powderly, Ani S Balmanoukian, Paul E Hoyle

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
John D Powderly, Martin E Gutierrez, Ani S Balmanoukian, Paul E Hoyle, Zhiwan Dong

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer, John D Powderly

J Immunother Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler

Cancer Res Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Edward B Garon, Alexander I Spira, Sarah B Goldberg, Jamie E Chaft, Vassiliki Papadimitrakopoulou, John D Powderly

J Thorac Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The application of autologous cancer immunotherapies in the age of memory-NK cells.
Gaby D Lizana-Vasquez, Madeline Torres-Lugo, R Brent Dixon, John D Powderly, Renaud F Warin

Front Immunol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, John D Powderly

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna

Oncologist· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield

J Immunother Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
George D Demetri, Jason J Luke, Antoine Hollebecque, John D Powderly, Alexander I Spira

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Lawrence Fong, Andrew Hotson, John D Powderly, Mario Sznol, Rebecca S Heist

Cancer Discov· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, John D Powderly

JAMA Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Omid Hamid, Luciana Molinero, Christopher R Bolen, Jeffrey A Sosman, Eva Muñoz-Couselo, John D Powderly

Clin Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Raffit Hassan, Anish Thomas, John J Nemunaitis, Manish R Patel, Jaafar Bennouna, John D Powderly

JAMA Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
David F McDermott, Jeffrey A Sosman, Mario Sznol, Christophe Massard, Michael S Gordon, John D Powderly

J Clin Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
David F McDermott, Charles G Drake, Mario Sznol, Toni K Choueiri, John D Powderly

J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Scott N Gettinger, Leora Horn, Leena Gandhi, David R Spigel, Scott J Antonia, John D Powderly

J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, John D Powderly

Nature· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential drug responses of circulating tumor cells within patient blood.
Andrew D Hughes, Jocelyn R Marshall, Eric Keller, John D Powderly, Bryan T Greene

Cancer Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, John D Powderly

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, John D Powderly

N Engl J Med· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid isolation of viable circulating tumor cells from patient blood samples.
Andrew D Hughes, Jeff Mattison, John D Powderly, Bryan T Greene, Michael R King

J Vis Exp· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microtube device for selectin-mediated capture of viable circulating tumor cells from blood.
Andrew D Hughes, Jeff Mattison, Laura T Western, John D Powderly, Bryan T Greene

Clin Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus

J Clin Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis